KTTA Stock Forecast

KTTA Stock Forecast 2022, 2023, 2024, 2025, 2030

Pasithea Therapeutics Corporation (NASDAQ: KTTA) – a revolutionary biotechnology business focusing on the research and development of innovative and effective therapies for mental and neurological problems – had its KTTA Stock Price rise by more than 135 percent pre-market yesterday. Pasithea Therapeutics Corporation announced that its wholly owned subsidiary Pasithea Clinics has been authorised to provide esketamine nasal spray (SPRAVATO) for treatment-resistant depressive disorders and has begun offering the treatment in its Knightsbridge, London location, which elicited a positive response from shareholders. Only three facilities in the United Kingdom have been certified to provide this therapy.

KEY QUOTES

“This is a significant achievement for our clinics in the United Kingdom and their clients. Globally, major depressive disorder is the main cause of long-term impairment. Available treatments are ineffective, and up to 30% of people with depression do not react to many trials of antidepressant medication. These people are thought to be suffering from treatment-resistant depression, and new therapeutic options are desperately required.” — Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics

“Esketamine is both safe and effective, especially when used in conjunction with continuous psychiatric care. Patients treated in outpatient settings must be engaged in a particular program due to various dangers connected with this medicine. We are really delighted to have been certified to deliver this therapy, which demonstrates our excellent quality of care.” — Dr. Yassine Bendiabdallah, Managing Director of Pasithea Clinics in the U.K.

What Does Pasithea Therapeutics Corporation Do?

Pasithea Therapeutics Corporation is a biotechnology business that conducts research and development of medicines for mental and neurological illnesses. Pasithea Therapeutics Corporation also plans to run anti-depression facilities and provide business advisory services by utilizing certified pharmacists to give ketamine intravenous infusions. Pasithea Therapeutics Corporation was founded in 2020 and is situated in Miami Beach, Florida.

Pasithea Therapeutics Stock News

Pasithea Therapeutics Stock is surging higher on Tuesday after the company announced the addition of esketamine nasal spray to its U.K. portfolio.

The esketamine nasal spray is available through Pasithea Therapeutics Corporation’s affiliate, Pasithea Clinics. Spravato is the brand name for this spray. The nasal spray is used to treat individuals suffering from depression who have not responded to previous therapies.

Pasithea Therapeutics Corporation states that the nasal spray is available at its Knightsbridge, London. Pasithea Therapeutics Corporation further emphasizes that just three locations in the United Kingdom have been licensed to provide this therapy.

In a press statement today, Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics Corporation, said the following.

“Major Depression is the main cause of long-term impairment globally. Current therapies are ineffective, with up to 30% of individuals with depression failing to respond to many trials of antidepressant medication. These people are thought to have treatment-resistant depression, and new therapeutic alternatives are desperately needed.”

According to Pasithea Therapeutics Corporation, esketamine is a safe and effective medication. Nevertheless, owing to specific hazards, only specific areas may provide it. That’s why it’s such a big deal that it’s introducing nasal spray to one of its facilities.

Of course, Pasithea Therapeutics Stock is being heavily traded in response to recent headlines. As of this writing, over 128 million shares of Pasithea Therapeutics Stock had changed hands. This is a significant increase over its daily average trading activity of around 512,000 shares.

As of Tuesday morning, KTTA Stock Price was up 221.8 percent.

What’s Happening with Pasithea Therapeutics Corp Stock This Week?

As of 9:38 a.m. on Tuesday, Nov. 23, Pasithea Therapeutics Stock was trading at $7.20, up $4.99, or 225.79 percent, from the last closing KTTA Stock Price of $2.21. Pasithea Therapeutics Stock is now trading between $3.70 to $4.95. On Tuesday, 21,059,871 Pasithea Therapeutics Stocks were exchanged, compared to a daily average of 475,165 shares.

14 Days Historical KTTA Stock Price Data

Date	Opening KTTA Stock Price	Closing KTTA Stock Price	Minimum KTTA Stock Price	Maximum KTTA Stock Price
2021-11-24	Open: 4.45	Close: 3.99	Low: 3.81	High: 4.45
2021-11-23	Open: 7.36	Close: 5.6	Low: 5.6	High: 7.61
2021-11-22	Open: 2.33	Close: 2.21	Low: 2.12	High: 2.33
2021-11-19	Open: 2.38	Close: 2.37	Low: 2.3	High: 2.39
2021-11-18	Open: 2.77	Close: 2.4	Low: 2.345	High: 2.77
2021-11-17	Open: 2.64	Close: 2.38	Low: 2.3	High: 2.64
2021-11-16	Open: 2.525	Close: 2.51	Low: 2.5	High: 2.535
2021-11-15	Open: 2.55	Close: 2.46	Low: 2.46	High: 2.55
2021-11-12	Open: 2.48	Close: 2.58	Low: 2.45	High: 2.58
2021-11-11	Open: 2.35	Close: 2.33	Low: 2.33	High: 2.35
2021-11-10	Open: 2.535	Close: 2.45	Low: 2.45	High: 2.535
2021-11-09	Open: 2.53	Close: 2.59	Low: 2.53	High: 2.6
2021-11-08	Open: 2.52	Close: 2.52	Low: 2.52	High: 2.53
2021-11-05	Open: 2.61	Close: 2.53	Low: 2.515	High: 2.64

Historical KTTA Stock Price Data:

Market Cap of KTTA Stock (Previous Close): 52.7 M
KTTA Stock Price in USD (Previous Close): 3.990
KTTA Stock Volume (Previous Close): 24.34 M
KTTA Stock Price in USD (Last): 3.990
90-Day Moving Average of KTTA Stock Price: 2.848
52 Week High KTTA Stock Price: 4.19
52 Week Low KTTA Stock Price: 2.21
KTTA Stock’s 50 Day Moving Average: 2.64
200 Day Moving Average of KTTA Stock: 2.74

KTTA Stock Price, Volume, and Earnings

Last KTTA Stock Price: $3.99
Previous Closing KTTA Stock Price: $3.99
Change: $0.00
Opening KTTA Stock Price: $4.30
KTTA Stock Volume: 25,778,199
Market Capitalization: $52.70M
14-Days Range KTTA Stock Price: $3.70 $4.95
52-week Range KTTA Stock Price: $2.10 $8.50